Chinanews.com, Beijing, August 19 (Reporter Zhang Su) Facing cancer patients around the world, well-known pharmaceutical companies in China and the United States will expand the PD-1 monoclonal antibody immuno-oncology drug Daboshu (sintilimab injection) Global strategic cooperation.

  "Taboshu successfully entered the National Medical Insurance Catalogue, making Cinda Bio's mission of'developing high-quality biopharmaceuticals affordable for ordinary people' a reality. Based on the success in the Chinese market, we are very happy to expand strategic cooperation with Eli Lilly. , To expand the cooperation field of Daboshu to the world." Yu Dechao, founder, chairman and president of Cinda Biopharmaceutical Group, said on the 19th.

  On the evening of the 18th, Cinda Biopharmaceutical Group and Eli Lilly and Company jointly announced the news of global strategic cooperation. According to the cooperation agreement, Cinda Biologics granted the exclusive license of Daboshu outside China to Eli Lilly and Company, which promotes the drug to North America, Europe and other regions. The total amount of this cooperation has exceeded 1 billion US dollars. Both parties will reserve the right to develop the products in their respective pipelines and the products of other partners.

  According to reports, Daboshu is an innovative drug jointly developed by Innovent and Eli Lilly. It was approved in China for the treatment of relapsed/refractory classic Hodgkin’s lymphoma in December 2018. It was published in the authoritative medical journal " The Lancet · Hematology. In November 2019, Daboshu entered the national medical insurance catalog.

  "We believe that Daboshu will benefit more patients around the world. This cooperation is also a good start for Daboshu and Cinda Bio to enter the world pharmaceutical stage." Yu Dechao said.

  The reporter learned that Cinda Bio has established a poverty alleviation fund to provide daboshu free of charge to cancer patients with family difficulties. At present, the R&D team is working hard to expand the scope of indications for Daboshu.

  In June of this year, Cinda Biotech and Roche Pharmaceuticals reached a cooperation of more than US$2 billion in the field of double antibodies and immune cell therapy. They have also established international cooperation with institutions such as the University of Texas MD Anderson Cancer Center. (Finish)